Entrectinib in children and young adults with solid or primary CNS tumors harboring <i>NTRK</i>, <i>ROS1</i>, or <i>ALK</i> aberrations (STARTRK-NG) - Concepedia

Concepedia

Publication | Open Access

Entrectinib in children and young adults with solid or primary CNS tumors harboring <i>NTRK</i>, <i>ROS1</i>, or <i>ALK</i> aberrations (STARTRK-NG)

DOI Full Paper Access

121

Citations

23

References

2022

Year

Ami V. Desai, Giles Robinson, Karen Gauvain, Ellen M. Basu, Margaret E. Macy, Luke Maese, Nicholas Whipple, Amit J. Sabnis, Jennifer H. Foster, Suzanne Shusterman,

Abstract

Entrectinib resulted in rapid and durable responses in pediatric patients with solid tumors harboring NTRK1/2/3 or ROS1 fusions.

References

	Year	Citations

Page 1